Morgan Stanley’s Cerevel Therapeutics Holdings, Inc. Warrant CEREW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-1,333
Closed -$6K 7905
2021
Q1
$6K Hold
1,333
﹤0.01% 7088
2020
Q4
$8K Buy
+1,333
New +$5.38K ﹤0.01% 6704

Other funds holding CEREW

Morgan Stanley's CEREW Position: Q2 2021 in Review

Morgan Stanley sold out of Cerevel Therapeutics Holdings, Inc. Warrant (CEREW) in Q2 2021, closing a stake of 1,333 shares — an estimated $6K sold.

Morgan Stanley first reported a position in CEREW in Q4 2020 and held it in 2 quarters. The position peaked at $8K in Q4 2020. 22 funds tracked by Wall St. Rank hold CEREW as of Q2 2021.

  • Morgan Stanley reported no remaining Cerevel Therapeutics Holdings, Inc. Warrant position as of Q2 2021 after selling out during the quarter.
  • Morgan Stanley sold 1,333 Cerevel Therapeutics Holdings, Inc. Warrant shares in Q2 2021, an estimated $6K.
  • Morgan Stanley first reported a position in Cerevel Therapeutics Holdings, Inc. Warrant in Q4 2020 and held it in 2 quarters.
  • Morgan Stanley's Cerevel Therapeutics Holdings, Inc. Warrant position peaked at $8K in Q4 2020.
  • 22 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Warrant as of Q2 2021.

Based on Morgan Stanley's 13F filing for Q2 2021, filed 16 Aug 2021.